Profit Guidance Lifted
Fisher & Paykel Healthcare Lifts FY27 Profit Outlook on Strong Product Demand
Key Points
The upgrade is presented as a mid-cycle guidance upgrade, a move analysts see as signaling management confidence in trading momentum.
management highlighted that recurring consumables revenue, paired with margin expansion, generally reflects a higher quality of earnings than reliance on one-off hardware sales.
Previous guidance issued in May 2026 covered a broader full-year range (revenue $2.45–$2.57 billion; NPAT $500–$550 million), with the August upgrade nudging the lower end of revenue higher to about $2.47 billion and NPAT to $525–$565 million.
Analyst sentiment remains a Hold, with a target price around NZ$42, according to TipRanks coverage.
Fisher & Paykel Healthcare has upgraded its 2027 profit outlook, projecting first-half revenue of NZ$1.24 billion and net profit after tax (NPAT) of NZ$280 million Kalkine, marking 14% revenue growth and 24% NPAT growth compared to the prior year. The company lifted its full-year guidance to operating revenue of NZ$2.47–2.57 billion and NPAT of NZ$525–565 million Grafa, buoyed by strong demand for hospital equipment and margin improvements across its consumables business.
The mid-cycle upgrade signals management confidence in sustained momentum Fool.com.au, driven by hospitals adopting newer hardware and shifts in clinical practice lifting consumables sales. The guidance assumes current tariff arrangements remain in place, and includes about NZ$23 million in US tariff refunds.
Hospital Demand Powers First-Half Growth
Fisher & Paykel's hospital product group is firing on all cylinders. First-half revenue hit NZ$1.24 billion Kalkine, a 14% jump year-over-year, driven by customer adoption of the company's latest hardware solutions. Management pointed to strong uptake in key hospital markets as the primary growth engine.
Consumables revenue is accelerating alongside hardware demand Fool.com.au. As hospitals install new equipment, they need more recurring supplies—a higher-quality earnings stream than one-time hardware sales. This shift in clinical practice is expected to sustain growth momentum through the full year.
Margin Expansion and Operational Efficiency Gains
The company is squeezing more profit from each dollar of sales. Management highlighted improvements in gross margin and operating efficiency Grafa as key drivers of the upgraded NPAT guidance of NZ$525–565 million for the full year. Continuous improvement initiatives across manufacturing and supply chain are paying dividends.
NPAT is projected to grow 24% Stockwirex, outpacing the 14% revenue growth rate. This margin expansion reflects better manufacturing productivity, improved product mix, and operational leverage as the company scales. The company expects these gains to continue through 2027 and beyond.
May Guidance Reset and August Refinement
Fisher & Paykel revised expectations upward just three months after issuing May 2026 guidance Kalkine. The earlier full-year range was NZ$2.45–2.57 billion in revenue and NZ$500–550 million in NPAT. August's upgrade nudged the revenue floor higher to NZ$2.47 billion and lifted NPAT to NZ$525–565 million, narrowing the range and boosting the midpoint.
The move signals rapid business acceleration mid-year Fool.com.au. Management confidence in trading momentum drove the more bullish stance. An August 2026 shareholders' meeting provided the opportunity to communicate the stronger outlook directly to investors, though analyst sentiment remains cautious with a Hold rating and a target price near NZ$42.
Tariff Refunds and Guidance Assumptions
The upgraded guidance includes approximately NZ$23 million in US tariff refunds Grafa, a one-time benefit that cushions full-year profits. However, management flagged a key assumption: the guidance assumes current tariff arrangements remain in place, meaning future trade policy changes could impact results.
Investors should note the tariff dependency in the outlook Stockwirex. While the refund boost is welcome, it masks some underlying business risk. If tariff conditions shift or new duties are imposed, the company's full-year profit range could face downward pressure, making the timing and sustainability of the upgrade dependent on trade policy stability.
Sentiment
Mostly PositivePublishers
10
Articles
13
Reach
23
